Liquid Biopsy Diagnostics Market - Strategic Insights and Forecasts (2026-2031)

The Liquid Biopsy Diagnostics market is forecast to grow at a CAGR of 17.6%, reaching USD 14.4 billion in 2031 from USD 6.4 billion in 2026.

The liquid biopsy diagnostics market includes tests that detect biomarkers such as circulating tumor DNA and circulating tumor cells from blood or other body fluids. Health agencies are incorporating liquid biopsies into clinical guidelines to improve early cancer detection, treatment monitoring, and personalized care.

Description

Liquid Biopsy Diagnostics refer to non-invasive diagnostic tests that identify tumor-derived genomic material (DNA), protein or cellular components within bodily fluids such as blood and urine. Liquid biopsy tests can play an important role in diagnosing cancer at an early stage, assessing the effectiveness of therapeutic agents, and monitoring for residual disease following treatment. With an increase in incidents of cancer globally, the demand for less invasive, rapid and repeatable diagnostic methodologies continues to grow. Regulatory authorities at the national and international level, including the U.S. Food and Drug Administration (FDA), have begun to modernise regulatory frameworks to permit the use of liquid biopsy assessments to be evaluated under current in vitro diagnostics regulations in terms of accuracy and clinical benefit. In addition, emergence of Public Health organisations such as the World Health Organisation (WHO) has supported innovations that promote earlier detection of cancer and broaden access to cancer screening in resource limited environments.

Liquid Biopsy Diagnostics Market Analysis

Growth Drivers

• Ascendance of Global Cancer Level: The rising incidence of cancer across the world is a key contributor to the increased demand of Liquid Biopsy products and services. The ability to detect tumor specific mutations with a liquid biopsy allows for a minimally invasive tool that can be used by clinicians and patients to monitor the progression of their disease over time, providing a much safer alternative than traditional tissue biopsies.

• Use of Non Invasive Testing Approaches: Tissue biopsies can be painful as well as risky due to their location and may also present a possible challenge with repeated sampling and monitoring of response to treatment. Liquid biopsies allow for continuous monitoring of the response to treatment and also allow for detection of emerging resistance mutations through a simple blood draw.

• Developments in Advanced Sensing/Sequencing Technologies and Bioinformatics Technologies: Because of the advancement of Next Generation Sequencing and Data Analytics Technology, the sensitivity and accuracy of detecting circulating tumor DNA has improved immensely. Advances in this technology have lead to improved confidence in the clinical utility of liquid biopsy and the potential to enable earlier detection of disease at earlier stages.

• Progress Toward Precision Medicine: Healthcare organizations are making a greater investment into Personalised Medicine and are increasing the availability of targeted therapies. Liquid Biopsy allows for selection of treatment based on the presence or absence of specific biomarkers so that therapy is tailored to individual patient needs as the treatment continues according to Precision Oncology Protocols.

Challenges and Opportunities

• The rapid expansion of the liquid biopsy market presents unique challenges for both technical and operational aspects. To successfully detect ctDNA (circulating tumor DNA) at very low concentrations, extreme levels of analytical sensitivity are required by the testing platform. Performance variability among different laboratories performing assays can also create inconsistencies in results for the same sample. High costs of testing and limited reimbursement in many regions will further limit widespread adoption of liquid biopsy. In addition, validation of clinical utility for detecting early-stage cancer will require large-scale longitudinal studies that could result in delays in the broader adoption of these tests in routine cancer screening programs. Implementation of liquid biopsy technology will also be more difficult in developing health care settings where access to advanced, high-throughput sequencing infrastructure is limited. Conversely, the opportunities for rapid expansion of liquid biopsy technology are rapidly increasing due to ongoing improvements in sequencing technologies and bioinformatics that increase the level of confidence in using liquid biopsy for early diagnosis and monitoring of minimal residual disease (MRD). In addition, the growth of liquid biopsy integration with precision oncology programs will enhance the ability to select appropriate targeted therapies (i.e., assess the patient's response to treatment) in real-time. Further, liquid biopsy is being utilised beyond the oncology setting (e.g., prenatal testing, organ transplant monitoring) creating additional uses for the technology. As more health care systems are prioritising non-invasive, repeatable diagnostic methodologies to improve the patient experience and ultimately improve clinical outcomes, liquid biopsy will be one of the main components of cancer management in the future.

Key Development

• May 2025: Guardant Health officially announced major enhancements to its Guardant360 Liquid test, introducing nearly a dozen new smart liquid biopsy applications enabled by its Guardant Infinity™ platform. These expanded capabilities allow clinicians to determine tumour phenotypes, confirm the absence of actionable mutations, classify cancer subtypes, and identify pharmacogenomic markers via a single blood sample. The updates also include detection of viral biomarkers such as HPV and EBV and evaluation of homologous recombination deficiency status, expanding the clinical insights available from liquid biopsies. These advancements broaden the test’s role in treatment selection, molecular tumour typing, and personalised cancer management, strengthening its utility in oncology care.

Market Segmentation

The market is segmented by product type, technology, application and geography.

By Product Type: Assays, Kits and Reagents

Kits & reagents have dominated sales volume due to their continual use in detecting blood-based biomarkers. They represent the primary consumables used to isolate circulating tumor DNA & other molecular markers, creating ongoing demand for kits & reagents in diagnostic labs & oncology clinics.

By Biomarker Type: Circulating Tumour DNA (ctDNA)

Circulating tumour DNA (ctDNA) has gained significant market adoption, allowing for the detection of mutations associated with specific cancers through a simple blood sample. ctDNA plays a key role in identifying actionable mutations, monitoring treatment response, & detecting residual disease in the precision oncology sector.

By Technology: Next Generation Sequencing (NGS)

Next-generation sequencing (NGS) enables comprehensive evaluation of multiple mutations by detecting them simultaneously in a single test. NGS has high sensitivity, allowing the detection of low-frequency DNA derived from tumours, aiding in early diagnosis & targeted therapies.

By Application: Treatment Monitoring

Liquid biopsy is being used more frequently to monitor patients’ response to therapy & identify the presence of resistance-associated mutations. Multiple blood tests allow providers to adjust their patients’ treatment regimens in real time & improve patient management long term.

Regional Analysis

North America Market Analysis

Due to its comprehensive health care systems, extensive availability of cancer screening and high uptake of molecular diagnostics technology, North America is viewed as the leader in the Liquid Biopsy Market sector. By developing pathways for the regulation of Liquid Biopsy assays via the U.S. Food and Drug Administration (FDA), the United States has provided an environment conducive to clinical use to oncology treatment providers. Top-tier cancer treatment and research institutions across the country are regularly employing Liquid Biopsy technology for selecting therapies, monitoring diseases and assessing minimal residual disease. The continued development of next-generation sequencing platforms and strong partnerships between diagnostic companies and health care systems will only serve to reinforce the region's sponsorship.

South America Market Analysis

South America is an emerging market where healthcare systems in Brazil, Argentina, and Chile are strengthening cancer diagnostics and laboratory capabilities. Public health initiatives and regional oncology research networks are supporting liquid biopsy integration for targeted therapy decisions and disease monitoring. Continued investment in molecular testing infrastructure and clinician education is driving incremental growth across the region.

Europe Market Analysis

In terms of levels of market advancement, Europe is experiencing consistent growth through enabling regulatory structures such as the In Vitro Diagnostic Regulation (IVDR) which mandates a standard of performance and clinical validation for testing of in vitro diagnostic devices. Certain European countries (such as Germany, the UK, and France) have established elements of Liquid Biopsy within their national cancer care strategies and integrated them with their precision oncology initiatives. Through a focus on early diagnosis and a strong inclination to utilize non-invasive testing, public healthcare systems are supportive of promoting the extensive use of Liquid Biopsy within Europe. Collaboration across organizational boundaries and utilization of the collaborative nature of pan-European research initiatives also contribute to the wider, clinically-based utilization of Liquid Biopsy.

Middle East and Africa Market Analysis

The Middle East is advancing adoption through investments in tertiary care facilities and cancer treatment centers in countries like the United Arab Emirates and Saudi Arabia. Liquid biopsy is increasingly used for therapy guidance and molecular profiling in urban healthcare environments. In Africa, adoption is emerging slowly due to limited infrastructure, but pilot programs and collaborations with international cancer research organizations are introducing molecular diagnostics into select clinical workflows.

Asia Pacific Market Analysis

The rapid growth of Liquid Biopsy in the Asia Pacific Region is primarily being established by increases in healthcare spending across several countries, including China, Japan, South Korea and Australia; by an increase in the incidence of cancers throughout the region; and through the installation of diagnostic laboratory capabilities that have been updated. Significant investments are ongoing in each of these countries for the development of capabilities relative to genomic testing and advanced molecular platforms. The growing understanding of the value of personalized medicine and the establishment of governmental programs throughout the region focusing on enhancing access to infrastructure for early cancer detection will promote increased demand for this market sector. Accelerated clinical and research utilization will also occur through strategic partnerships with established global technology organizations.

List of Companies

• Guardant Health

• Roche Diagnostics

• Illumina

• Thermo Fisher Scientific

• QIAGEN

• Bio-Rad Laboratories

• Exact Sciences

• Freenome

• GRAIL

• Agilent Technologies

Roche Diagnostics

Roche Diagnostics is a globally recognised leader in molecular diagnostic products, tools, and technologies. Within its product offerings, one can find real-time PCR systems, high-throughput testing solutions, and companion diagnostics used for oncological, infectious diseases, and genetic testing. Its diagnostic technology facilitates laboratory automation and collaboration through integration with laboratory information systems, allowing for optimal workflows and data management. Roche also manufactures multiplex assays to enable the simultaneous detection of various pathogens. Furthermore, Roche's continuous investments in new technologies, including next-generation sequencing and biomarker discovery, are helping to solidify its role in the field of precision medicine. The breadth of Roche's portfolio and its global reach establish it as one of the leading diagnostic companies, helping to make it an essential component of clinical and reference labs.

Thermo Fisher Scientific

Thermo Fisher Scientific is a manufacturer and distributor of many types of molecular diagnostic technologies, including PCR technology, next-generation sequencing technology, reagents, and bioinformatics software. Thermo Fisher's Applied Biosystems brand manufactures and sells products that relate to genetic analysis, infectious disease identification, and research purposes. Additionally, Thermo Fisher's platforms provide high-throughput workflows, allowing labs to increase their testing capacity. Thermo Fisher also offers package solutions for integrated service/support to help labs achieve optimal assay performance and compliance. Thermo Fisher is well-known for its strong commitment to research and development in order to support ongoing innovation in molecular testing and laboratory automation, positioning it to be a critical partner for clinical and research labs globally.

Liquid Biopsy Diagnostics Market Scope: